Louise Saul1, Debra H Josephs1, Keith Cutler2, Andrew Bradwell2, Panagiotis Karagiannis3, Chris Selkirk4, Hannah J Gould5, Paul Jones6, James F Spicer7, Sophia N Karagiannis3. 1. Cutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK; Research Oncology, Division of Cancer Studies; King's College London; Guy's Hospital; Great Maze Pond; London, UK. 2. Public Health England; Porton Down; Salisbury, Wiltshire UK. 3. Cutaneous Medicine and Immunotherapy; St. John's Institute of Dermatology; Division of Genetics and Molecular Medicine & NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's College London; London, UK. 4. Biotherapeutics Development Unit; Cancer Research UK; South Mimms, Hertfordshire UK. 5. Randall Division of Cell and Molecular Biophysics & Division of Asthma; Allergy and Lung Biology, MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London; London, UK. 6. Drug Development Office; Strategy and Research Funding; Cancer Research UK; London, UK. 7. Research Oncology, Division of Cancer Studies; King's College London; Guy's Hospital; Great Maze Pond; London, UK.
Abstract
BACKGROUND: Due to genetic similarities with humans, primates of the macaque genus such as the cynomolgus monkey are often chosen as models for toxicology studies of antibody therapies. IgE therapeutics in development depend upon engagement with the FcεRI and FcεRII receptors on immune effector cells for their function. Only limited knowledge of the primate IgE immune system is available to inform the choice of models for mechanistic and safety evaluations. METHODS: The recognition of human IgE by peripheral blood lymphocytes from cynomolgus monkey and man was compared. We used effector cells from each species in ex vivo affinity, dose-response, antibody-receptor dissociation and potency assays. RESULTS: We report cross-reactivity of human IgE Fc with cynomolgus monkey cells, and comparable binding kinetics to peripheral blood lymphocytes from both species. In competition and dissociation assays, however, human IgE dissociated faster from cynomolgus monkey compared with human effector cells. Differences in association and dissociation kinetics were reflected in effector cell potency assays of IgE-mediated target cell killing, with higher concentrations of human IgE needed to elicit effector response in the cynomolgus monkey system. Additionally, human IgE binding on immune effector cells yielded significantly different cytokine release profiles in each species. CONCLUSION: These data suggest that human IgE binds with different characteristics to human and cynomolgus monkey IgE effector cells. This is likely to affect the potency of IgE effector functions in these two species, and so has relevance for the selection of biologically-relevant model systems when designing pre-clinical toxicology and functional studies.
BACKGROUND: Due to genetic similarities with humans, primates of the macaque genus such as the cynomolgus monkey are often chosen as models for toxicology studies of antibody therapies. IgE therapeutics in development depend upon engagement with the FcεRI and FcεRII receptors on immune effector cells for their function. Only limited knowledge of the primate IgE immune system is available to inform the choice of models for mechanistic and safety evaluations. METHODS: The recognition of human IgE by peripheral blood lymphocytes from cynomolgus monkey and man was compared. We used effector cells from each species in ex vivo affinity, dose-response, antibody-receptor dissociation and potency assays. RESULTS: We report cross-reactivity of human IgE Fc with cynomolgus monkey cells, and comparable binding kinetics to peripheral blood lymphocytes from both species. In competition and dissociation assays, however, human IgE dissociated faster from cynomolgus monkey compared with human effector cells. Differences in association and dissociation kinetics were reflected in effector cell potency assays of IgE-mediated target cell killing, with higher concentrations of human IgE needed to elicit effector response in the cynomolgus monkey system. Additionally, human IgE binding on immune effector cells yielded significantly different cytokine release profiles in each species. CONCLUSION: These data suggest that human IgE binds with different characteristics to human and cynomolgus monkey IgE effector cells. This is likely to affect the potency of IgE effector functions in these two species, and so has relevance for the selection of biologically-relevant model systems when designing pre-clinical toxicology and functional studies.
Authors: M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins Journal: Bioinformatics Date: 2007-09-10 Impact factor: 6.937
Authors: H J Gould; G A Mackay; S N Karagiannis; C M O'Toole; P J Marsh; B E Daniel; L R Coney; V R Zurawski; M Joseph; M Capron; M Gilbert; G F Murphy; R Korngold Journal: Eur J Immunol Date: 1999-11 Impact factor: 5.532
Authors: Sophia N Karagiannis; Marguerite G Bracher; James Hunt; Natalie McCloskey; Rebecca L Beavil; Andrew J Beavil; David J Fear; Richard G Thompson; Nicholas East; Frances Burke; Robert J Moore; David D Dombrowicz; Frances R Balkwill; Hannah J Gould Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Jitesh Chauhan; Alex J McCraw; Mano Nakamura; Gabriel Osborn; Heng Sheng Sow; Vivienne F Cox; Chara Stavraka; Debra H Josephs; James F Spicer; Sophia N Karagiannis; Heather J Bax Journal: Antibodies (Basel) Date: 2020-10-16
Authors: E Jensen-Jarolim; H J Bax; R Bianchini; M Capron; C Corrigan; M Castells; D Dombrowicz; T R Daniels-Wells; J Fazekas; E Fiebiger; S Gatault; H J Gould; J Janda; D H Josephs; P Karagiannis; F Levi-Schaffer; A Meshcheryakova; D Mechtcheriakova; Y Mekori; F Mungenast; E A Nigro; M L Penichet; F Redegeld; L Saul; J Singer; J F Spicer; A G Siccardi; E Spillner; M C Turner; E Untersmayr; L Vangelista; S N Karagiannis Journal: Allergy Date: 2017-01-23 Impact factor: 13.146
Authors: Mohammad Fereydouni; Mona Motaghed; Elnaz Ahani; Tal Kafri; Kristen Dellinger; Dean D Metcalfe; Christopher L Kepley Journal: Front Oncol Date: 2022-03-31 Impact factor: 6.244
Authors: Panagiotis Karagiannis; Federica Villanova; Debra H Josephs; Isabel Correa; Mieke Van Hemelrijck; Carl Hobbs; Louise Saul; Isioma U Egbuniwe; Isabella Tosi; Kristina M Ilieva; Emma Kent; Eduardo Calonje; Mark Harries; Ian Fentiman; Joyce Taylor-Papadimitriou; Joy Burchell; James F Spicer; Katie E Lacy; Frank O Nestle; Sophia N Karagiannis Journal: Oncoimmunology Date: 2015-06-03 Impact factor: 8.110
Authors: Anthony Cheung; Heather J Bax; Debra H Josephs; Kristina M Ilieva; Giulia Pellizzari; James Opzoomer; Jacinta Bloomfield; Matthew Fittall; Anita Grigoriadis; Mariangela Figini; Silvana Canevari; James F Spicer; Andrew N Tutt; Sophia N Karagiannis Journal: Oncotarget Date: 2016-08-09